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DigoxigeninWe applied noncovalent complexes of digoxigenin (Dig) binding antibodies with digoxigeninylated peptide
derivatives to modulate their pharmacokinetic properties. A peptide derivative which activates the Y2R
receptor was selectively mono-digoxigeninylated by reacting a NHS-Dig derivative with an ε-amino group
of lysine 2. This position tolerates modiﬁcations without destroying receptor binding and functionality of
the peptide. Dig-peptide derivatives can be loaded onto Dig-binding IgGs in a simple and robust reaction,
thereby generating peptide–IgG complexes in a deﬁned two to one molar ratio. This indicates that each
antibody arm becomes occupied by one haptenylated peptide. In vitro receptor binding and signaling assays
showed that Dig-peptides as well as the peptide–antibody complexes retain better potency than the corre-
sponding pegylated peptides. In vivo analyses revealed prolonged serum half-life of antibody-complexed
peptides compared to unmodiﬁed peptides. Thus, complexes are of sufﬁcient stability for PK modulation. We
observed more prolonged weight reduction in a murine diet-induced obesity (DIO) model with antibody-
complexed peptides compared to unmodiﬁed peptides. We conclude that antibody–hapten complexation can
be applied to modulate the PK of haptenylated peptides and in consequence improve the therapeutic efﬁcacy
of therapeutic peptides.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
One major hurdle that needs to be overcome for effective therapeutic
application of peptides and peptide derivatives is limited in vivo stability
and unfavorable PK properties. Their size is small compared to proteins,
and in most cases lies below the exclusion limit for renal ﬁltration.
These features,which apply tomost therapeutic peptide candidates trans-
late into short serum half-life and fast in vivo clearance [1]. Various tech-
nologies are currently being applied to address these issues [2]. One
established approach to improve PK, stability and biophysical behavior
of therapeutic peptides is to fuse them to proteinmoduleswhich stabilize
peptides, increase their solubility, and extend their serumhalf-life. Exam-
ples for that are fusions to serum albumin or to IgGs [3–5]. While thisoxigenin; SEC, size exclusion
-chain, heavy chain; L-chain,
arly Development, Nonnenwald
ann).
.V. Open access under CC BY-NC-ND liapproach works in many cases for linear peptides composed of natural
amino acids (which tolerate fusion at either their C or N-termini without
loss of activity), peptides that are cyclized, stapled, or which contain un-
natural amino acids or additional structures cannot be generated by trans-
lation and hence cannot be produced as recombinant antibody fusion
proteins. However, such peptidesmay be the desired choice for therapeu-
tic applications because they are frequently superior to ‘normal’ linear
peptides in terms of activity and speciﬁcity [6,7]. Another established ap-
proach to improve PK/stability and biophysical behavior of therapeutic
peptides including those that are cyclized, stapled, or contain unnatural
structures is the addition of polymers such as PEG or HES [8–11]. How-
ever modiﬁcations like PEGylation or HESylation frequently lead to sig-
niﬁcant reduction of the activity and under certain circumstances may
raise safety or potential toxicity issues [7]. One additional approach to
modulate the PK of ‘artiﬁcial’ peptides can be achieved by chemical
conjugation to proteins, or by covalent coupling to catalytic antibodies
[12,13]. A potential issue of these technologies is that aﬁxed attachment
of peptides via unnatural chemical structures to a protein may generate
immunogenicity issues because covalently linked non-human struc-
tures can be actively displayed by antigen presenting cells. Further-
more, tight covalent linkage opens no possibility for the peptide to
be released at any time. Another disadvantage of most existing chem-
ical coupling technologies for stabilization or PK modulation ofcense.
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involve not only chemical coupling steps, but also result in many
cases in mixtures of peptide derivatives that are connected to
PK-modulating agents with uncertain stoichiometries and/or at
undeﬁned positions. Furthermore, currently used peptide conjugation-
or modiﬁcation-techniques may result in strongly reduced or even loss
of biological activity of the therapeutic agent.
This work describes a novel approach towards overcoming these
limitations, generating a robust platform to enable PK-modulation
without encountering loss of biological activity. We combined hapten-
binding antibodies with haptenylated peptides to generate antibody–
peptide complexes. Non-covalent connection between antibody and
payload may also reduce immunogenicity risks because haptens
become released upon proteolytic degradation of the antibody and
hence cannot be displayed on antigen presenting cells. As an example
for this technology, noncovalent complexes of Dig-binding antibodies
with a digoxigeninylated PYY(3–36) derivative were generated and
characterized in vitro and in vivo.
2. Materials and methods
2.1. Dig-binding antibodies
Dig-binding antibodies for this study were the murine IgG 19–11
derived from hybridoma [14,15], and a recombinant humanized deriv-
ative of this antibody [16]. Recombinant antibodies were transiently
expressed in HEK293 suspension cells by co-transfecting light- and
heavy-chain expression plasmids, and subsequent 7 d cultivation in
serum free medium at 37 °C as previously described [17]. Antibodies
were puriﬁed from cleared supernatants by protein-A and SEC. Protein
concentrations were determined by measuring optical density (OD)
at 280 nm and product homogeneity was determined by analytical
SEC and SDS-PAGE. A detailed description of antibody generation and
characterization is provided in the supplement.
2.2. Generation of Dig-moPYY and Dig-Cy5
The PYY(3–36)-peptide derivative (moPYY, [18]) was obtained by
automated solid-phase synthesis of the resin-bound peptide sequence
Ac-IK(Dde)-Pqa-R(Pbf)H(Trt)Y(tBu)LN(Trt)W(Boc)VT(tBu)R(Pbf)Q(Trt)-
MeArg(Mtr)-Y(tBu)-TentaGel-RAM according to the established proto-
cols using Fmoc chemistry. The ivDde groupwas removed by hydrazine
hydrate and the 12-amino-4,7,10-trioxadodecanoic acid (TEG)-linker
was coupled with HATU/HOAt onto the Lys2 side-chain. After cleavage
from the resin, the peptide was precipitated with cold diisopropyl
ether and lyophilized to give a colorless solid. This was used for the
subsequent manipulation without further puriﬁcation. For preparation
of DIG-moPYY, Dig-3-carboxy-methyl-N-hydroxysuccinimide (1 eq.)
dissolved in NMP and triethylamine (2 eq.) was added to the peptide
solution in water, followed by the second addition (0.5 eq.) after 2 h
incubation at room temperature. Dig-moPYY was puriﬁed by prepara-
tive reversed phase HPLC employing an acetonitrile/water gradient
containing 0.1% TFA to furnish the Dig-moPYY peptide as a colorless
solid. Product identity was demonstrated by ESI-MS. The generation
of Dig-Cy5 by reacting Cy5 with DIG-carboxymethyl-NHS ester (DE
3836656) was previously described [16,17]. Detailed descriptions of
the generation and analytics of Dig-moPYY and Dig-Cy5 are provided
as supplemental data.
2.3. Generation of site-speciﬁc complexes of antibodies with Dig-moPYY
and Dig-Cy5
To generate complexes of Dig-moPYY with the hybridoma-
derived bDigNIgG, the mubIgGN was dissolved in 12 ml water and
dialyzed against 20 mM His, 140 mM NaCl; pH 6.0 to yield 300 mg
(2 × 10−6 mol) in 11 ml buffer (c = 27.3 mg/ml). DIG-moPYY(11.57 mg, 4 × 10−6 mol, 2 eq.) was added in 4 portions of 2.85 mg
within 1 h and incubated for another hour at RT. Thereafter, peptide–
IgG complexes were puriﬁed by SEC (Superdex 200 26/60 GL) in
20 mMHistidine, 140 mMNaCl at pH 6.0. Eluted complexwas collected
in 4 ml fractions, pooled and sterilized (0.2 μm ﬁlter) to give 234 mg
of the IgG/peptide complex at 14.3 mg/ml. To generate peptide com-
plexes with humanized IgG, hubDiN (10.6 mg/ml = 9.81 mg,
6.5 × 10–8 mol in 0.93 ml) in 20 mM His, 140 mM NaCl, pH 6.0) was
mixed with 0.57 mg = 1.97 × 10–7 mol = 3.03 eq. of DIG-moPYY
lyophilisate and incubated for 1.5 h at RT. The excess of peptide was re-
moved by SEC (Superose 6 10/300 GL column in 20 mM His/140 mM
NaCl/pH 6.0, 0.5 ml/min). The eluted complex was sterilized (0.2 μm
ﬁlter) and yielded 4.7 mg IgG/peptide complex at a concentration
of 1.86 mg/ml. Antibody–ﬂuorophore complexes were produced by
mixing Dig-Cy5 and IgG to a 2:1 ﬁnal molar ratio Dig-Cy5 to IgG. For
example, Dig-Cy5 in PBS (ﬁnal concentration of 0.5 mg/ml) was incu-
bated for a total of 2 hwith IgG inHis/NaCl pH 6 buffer. To analyze com-
plex composition by SEC-MALS, 100–500 μg of samples were applied to
a Superdex 200 10/300 GL SEC column (0.25–0.5 ml/min with 1 × PBS
pH 7.4 as mobile phase). Light scattering was detected with a Wyatt
miniDawn TREOS/QELS and refractive index was measured with a
Wyatt Optilab rEX-detector. The software ASTRA (version 5.3.4.14)
was applied for data analyses to yield complex mass, radius and size.
2.4. In vitro activity of antibody complexes
cAMP agonist assays (Tropix cAMP-ScreenKits)were performedwith
10.000 hNPY2R expressing HEK293/hNPY2R cells/well [18] in 384-well
plates (in DMEM/F12 w/o phenol red + 10% heat-inactivated FBS +
1% Pen/Strep + 500 μg/ml G418). Plates were incubated at 37 °C
overnight, then the medium was exchanged with DMEM/F12
containing 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Calbiochem)
and 0.5 mg/ml BSA, with a ﬁnal DMSO concentration of 1.1% and
a Forskolin (Calbiochem) concentration of 5 μM. The plates were incu-
bated at RT for 30 min, the media were discarded and 50 μl/well of
Assay Lysis Buffer (Tropix) was added and incubated for 45 min at
37 °C. 20 μl lysate was transferred into pre-coated plates of a cAMP
ELISA System (Applied Biosystems) to detect the cAMP generated.
2.5. Determination of serum concentrations of Dig-Cy5 and Dig-moPYY
For all animal experiments, experimental study protocols were
reviewed and approved by the local government. All studies were
performed in an AAALAC International approved animal facility. For
Cy5 determination, 32.1 nmol of Dig-Cy5, or antibody complexated
compound was applied to 2 female mice (strain NRMI) for each. The
mice had a weight between 24 g and 25 g. About 0.1 ml blood samples
were collected after 0.08 h, 2 h and 24 h for Mouse 1 and 0.08 h, 4 h
24 h for Mouse 2. Serum samples of at least 40 μl were obtained and
stored at−80 °C. Cy5 ﬂuorescence was measured using a Cary Eclipse
Fluorescence Spectrophotometer (Varian), with excitation at 649 nm
and detection at 670 nm. Samples were diluted in PBS to reach an
appropriate range of emission intensity. Serum of an untreated mouse
diluted in an identical manner was used as reference. To determine
serum concentrations of Dig-moPYY, 32.1 nmol of uncomplexed or
complexed peptide (in His/NaCl buffer) was applied to 2 female mice
(strain NRMI, between 23 and 28 g) for each substance. 0.1 ml blood
samples were collected after 0.08 h, 2 h and 24 h for Mouse 1 and
0.08 h, 4 h 24 h for Mouse 2. Serum samples (40 μl) were obtained
after 1 h and stored at−80 °C. Dig-PYY was determined by Western-
blot: 2 μl serum sample was diluted in 18 μl His/NaCl buffer, mixed
with 6.7 μl of 4× SDS sample buffer and 3 μl of 10× sample reducing
agent (NuPAGE, Invitrogen) for 5 min at 95 °C. As a control, 2 μl of
serum of an untreated mouse of the same strain was used. Samples
were applied to and proteins/peptides separated on a 4–12% reducing
SDS-PAGE, and subsequently blotted onto a PVDF membrane (0.22 μm,
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Tween-20 (PBST) for 1 h at RT), Dig-moPYY was detected on the
membrane with anti-digoxigenin antibodies (MAKbDIGNM-19–11-
IgG(SP/Q)), applied at 13 μg/ml in 10 ml of 1% skim milk/PBST for 2 h
at RT, followed by exposure to POD-coupled anti-Mouse IgG Fab-
fragments (Roche LumiLightPLUS Western Blotting Kit reagent) and
blot development by incubation with 4 ml LumiLight substrate for
5 min at RT followed by chemiluminescence detection.
2.6. In vivo activity of Dig-moPYY–IgG complexes
To determine the effect of NPY2-receptor agonists on food intake,
we administered uncomplexed and antibody complexed moPYY to
DIO mice. Adult male C57Bl/6 mice (Jackson Labs) were placed on
a high fat diet (HFD; 60% of dietary kcal as fat, BioServe F3282) for
over 20 weeks to induce obesity. The mice were then sorted by body
weight and 24 h food intake, and housed individually in standard
caging at 22 °C in a reversed 12-h light/12-h dark cycle, and were
acclimated to these conditions for at least 6 days before start of the
experiment. Food (HFD) and water were provided ad libitum through-
out the study. Proteins, peptides and controls were injected subcutane-
ously at the beginning of the dark cycle and food intake was measured
at various time intervals up to 96 h post-dosing (N = 6–8mice/group).
Uncomplexed Dig-moPYY was administered at 11.05 μMol/kg, antibody-
complexed DIG-moPYY at a concentration of 0.62 μMol/kg. Thus, the
injected molar concentration of the antibody complexed peptide was
more than 17-fold lower than that of the uncomplexed peptide.
3. Results
3.1. Digoxigenin-binding antibodies
Murine as well as recombinant humanized digoxigenin (Dig)-
binding antibodies were applied for the production of antibody com-
plexes with haptenylated peptide derivatives. The murine Dig-binding
antibody that was used in this study was produced by and puriﬁed
from hybridoma cell supernatants [14,15]. The corresponding human-
ized derivative was recombinantly produced in mammalian cells as
previously described [16] (details in Suppl. data). Both antibodies
were puriﬁed from culture supernatants to homogeneity by protein-A
and size exclusion chromatography. Their composition, purity and
homogeneity are shown in Fig. 1 and Suppl. Fig. S1. Previous analyses
indicated that the antibodies bind Dig and Dig-payloads with approx.
15 nM afﬁnity as determined by SPR analyses [16] in a deep pocket
that is formed by the CDR's of the Fv region [16]. Within the complex,
bound Dig is completely covered, with linker and attached payload fac-
ing towards the outside of the surface of the pocket ([16],www.pdb.org,
PDB ID: 3RA7, Fig. 1b).Fig. 1. Composition of the Dig-binding antibody with complexed Dig-peptide and Dig-
ﬂuorophore (a) and structure of the Dig-binding site (b).3.2. Synthesis of digoxigeninylated peptides and ﬂuorophores
To achieve optimal complex formation between antibody and Dig-
peptide (or ﬂuorophore), interference of antibody binding by steric
hindrance must be avoided. We therefore placed short but ﬂexible
linker stretches between Dig and payload. The strategies for synthesis
and the compositions of Dig-coupled compounds are summarized in
Fig. 2 and Suppl. Fig. S2: Dig-NHS derivatives are versatile building
blocks to attach Dig-derivatives to amino groups (Fig. 2a). The mole-
cules have a molecular weight of 565.6 and 658.8 respectively. They
consist of the digoxigenin core structure derivatized at the hydroxyl
group in position 3 with an acetamido residue, which is connected via
an aminohexanoic acid spacer ((Dig-3-carboxymethyl)amino-hexanoic
acid N-hydroxysuccinimide (NHS) ester) or directly to an 3-carboxy-
methyl NHS ester.
The peptide derivative that we selected to test our technology is
depicted in Fig. 2c. It is analog to Peptide Tyrosine Tyrosine or Pancreatic
Peptide YY short PYY(3–36) [19–21]. It consists of the acetylated N-
terminal amino acids Ile-Lys of PYY(3–36) connected via N-piperazin-
1-yl-4(3H)-quinazolinone-3-acetic acid to the amidated C-terminal
α-helix 25–36. Furthermore, it has Leu30 changed to Trp30 and Arg35 to
N-Me-Arg35 (Ac-IK-Pqa-RHYLNWVTRQ(N-methyl)RY-NH2) [18]. This
[Pqa5-24]PYY(3–36) analog is termed moPYY (modiﬁed PYY) in this
work. PYY(3–36) and moPYY bind to and thereby modulate the Y2
receptor (Y2R) of the NPY receptor family. PYY is secreted by the neuro-
endocrine cells in the ileum and colon in response to a meal, inhibits
gastric motility, increases digestion and nutrient absorption, and
reduces appetite [18,22,23]. Because PYY plays a crucial role in energy
homeostasis by balancing food intake, peptides of this typemaybeuseful
to treat type II diabetes and obesity. This peptide is highly and speciﬁcally
active in vitro (see below), but it has the disadvantage of limited stability
and short serum half-life in vivo. moPYY was obtained by sequential
coupling and assembly in iterative cycles via automated solid-phase syn-
thesis using Fmoc chemistry (see theMaterials andmethods section for a
detailed description of the synthesis). The side-chain of Lys in position
2 was protected by the orthogonal Dde protecting group. Dde was
removed selectively with hydrazine hydrate in order to introduce TEG
as a spacer on the side chain. After cleavage from the resin with simulta-
neous deprotection of the peptide, the Lys(TEG)-ω-amino group was
reacted with digoxigenin-3-carboxy-methyl-N-hydroxysuccinimide to
generate the digoxigeninylated compound Ac-IK(Dig-3-CME-TEG)-Pqa-
RHYLNWVTRQ-MeArg-Y-NH2 (short: Dig-moPYY). The structure of
moPYY with digoxigenin attached to the side chain of the unique lysine
in position 2 of the peptide is shown in Fig. 2c. This molecule has the
Dig-moiety attached to the same position as the PEGylated derivative
PEG-moPYY ([18], Fig. 2d). The product was puriﬁed by preparative
reversed phase HPLC employing an acetonitrile/water gradient con-
taining 0.1% TFA to furnish the Dig-moPYY peptide (29 mg, 10.0 μmol,
25%). We also produced a digoxigeninylated Cy5 molecule (Dig-Cy5,
Fig. 2e) to serve as ‘peptide surrogate’ to enable robust detection
of antibody complexes by the ﬂuorescence properties of Cy5. For
that, Dig-carboxymethyl-NHS ester was transformed with mono-Boc-
ethylendiamine. After Boc removal the released amine was reacted
with Cy5-NHS ester and puriﬁed by reversed phase chromatography
(details see the Materials and methods section and Suppl. S2, [16]).
The compound is soluble in aqueous solution. The molecular weight of
Cy5 is 791.99 Da and that of the Cy5-Dig conjugate is 1167.55 Da.
3.3. Dig-mo PYY and Dig-ﬂuorophores form deﬁned complexes with
Dig-binding antibodies
For the generation of antibody complexes we applied a simple and
robust ‘charging reaction’. Due to the bivalency of IgG's, a deﬁned
stoichiometry of 2 Dig-payloads to one IgG was expected and desired.
For peptide-complex generation, Dig-moPYY was incubated with Dig-






































































Fig. 2. Dig-peptides and ﬂuorophores. (a) Dig-NHS with short (left) and long (right) spacer between NHS and Dig, (b) Dig-Cy5, (c) moPYY, (d) Dig-moPYY, and (e) PEG-moPYY.
51E. Hoffmann et al. / Journal of Controlled Release 171 (2013) 48–56between 10 and 30 mg/ml (IgG). Dig-peptide was subsequently added
in aliquots until the molar IgG and peptide concentrations reached a
2:1 ratio (details in the Materials and methods section). As an example
for this reaction, 2 × 10−6 mol IgG in 11 ml aqueous histidine buffer
(300 mg, c = 27.3 mg/ml) was combined with 4 aliquots of 1 ×
10−6 mol Dig-moPYY (a total 11.57 mg, 4 × 10−6 mol) within 1 h
and incubated for another hour at room temperature. After completion
of the reaction, the peptide–IgG complexes were puriﬁed by size
exclusion chromatography (Superdex 200) chromatography (Fig. 3a).
The eluted fractions containing the complex were pooled and subse-
quently sterilized (0.2 μmﬁltration), yielding 234 mgof the IgG/peptide
complex at a concentration of 14.3 mg/ml. The resulting preparation
is composed of IgG-like molecules which carry 2 Dig-peptides per
one antibody derivative. This was demonstrated by size exclusion chro-
matography, which also indicated the absence of protein aggregates
(Fig. 3a). Deﬁned composition and 2:1 charging ratios were further con-
ﬁrmed by SEC-MALS analyses (size exclusion chromatography-multi
angle light scattering, Fig. 3b). These SEC MALS analyses provided
further information about the mass, size and homogeneity of the com-
plexes, in comparison to the corresponding uncharged antibody, and
conﬁrmed that exposure of Dig-moPYY to the Dig-binding antibody
results in complexes that contain two Dig-moPYY derivatives per one
bivalent IgG. Thus, Dig-moPYY can be complexed with the Dig-binding
antibody at deﬁned sites (binding region) andwith a deﬁned stoichiom-
etry. The binding complexes appear to be stable because they do not dis-
sociate within the time period and under the experimental conditions
that are associated with the SEC and analytical SEC-MALS procedures.
Antibody complexes with Dig-Cy5 were generated in a similar
manner, again performing the charging reaction in 2:1 (ﬂuorophore
to IgG) ratio in aqueous buffer (further details in the Materials
and methods section). Charging of the antibody can be determined by
measuring the ﬂuorescence (650/667 nm) of the antibody-associated
ﬂuorophore on a size exclusion column. The results of these experiments[16] demonstrated again that charging occurs only if the antibody
contains digoxigenin binding sites, and that increased charging signals
are observed for Dig-binding antibody derivatives until a Dig-Cy5 to
IgG ratio of 2:1 is reached. Like peptide complexes, Dig-Cy5 complexes
appear rather stable because we see no evidence for dissociation within
the time period and under the experimental conditions that are associat-
ed with analytical section. To evaluate the stability of complexes under
conditions that are similar to in-vivo, Dig-Cy5–antibody complexes were
also incubated at 37 °C in murine serum, followed by protein-A medi-
ated antibody capture and subsequent determination of IgG-bound
payload by ﬂuorescence detection. The results of these experiments
(details in Suppl. S3 data, Suppl. Fig. S3) conﬁrmed that Dig-Cy5 stays
attached to antibody (or rebinds antibody in equilibrium) equally well
(for N24 h) in serum at 37 °C as observed in buffer.
3.4. Dig-moPYY–antibody complexes retain Y2R modulating functionality
in vitro
The most important parameter that needs to be addressed for any
technology aimed at antibody-complexation is that the functionality
of the compound is retained. Our approach carries two modulation
steps for peptides: In a ﬁrst stepwe covalently couple Dig to the peptide.
In a second step, this Dig-peptide is complexedwith the antibody deriv-
ative, which is a large protein. To retain activity of the peptide it is
important to assure activity of modiﬁed peptide for both steps. Activity
assays need to show that (i) functionality of the peptide is retained
after digoxigenation, and (ii) functionality is retained after com-
plexation of digoxigeninylated peptide to the murine or humanized
bDigNIgG. We therefore compared the biological activity of unmodiﬁed
and digoxigeninylated moPYY, and their complexes with bDigNIgG.
PYY-derived peptides bind to and promote signaling of its cognate
receptor NPY2-receptor which in turn regulates metabolic processes
[20]. The modulation of this signaling pathway can be assessed in vitro
Fig. 3. Charging of anti-DIG antibody with Dig-PYY. (a) SEC demonstrates that peptide complexation results in a complex of deﬁned size. (b) SEC-MALS analyses demonstrate that
antibody complexation of Dig-peptides results in a complex of deﬁned size which is larger than that of the uncomplexed antibody or uncomplexed peptide, with 2 peptides per
antibody derivative.
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cAMP accumulation in HEK293 cells expressing the NPY2 receptor
(cAMP-assay, [18], assay details see theMaterials andmethods section).
To analyze if the modiﬁcations and antibody complexation of moPYY
with digoxigenin affect its functionality, we measured its function-
ality in this assay and compared it with that of the unmodiﬁed and
PEGylated peptide. The results of these assays are shown in Fig. 4.
The digoxigeninylated peptide derivative retains most of the activi-
ty of the parent molecule, with IC50 values of 0.012 nM for the
unmodiﬁed peptide, 0.12 nM for the modiﬁed analog and 0.42 nM
for the digoxigeninylated peptide. Thus, digoxigenation was accompa-
nied by a tolerable 3.5-fold reduction in biological activity compared
to moPYY. Complexation with a large bDigNIgG had only a modest
inﬂuence on activity of the Dig-peptide: The IC50 value in the cAMP
assay was 2.4 nM for the peptide–antibody complex. In contrast, a
PYY derivative that is PEGylated at the same position as Dig-moPYY,
but otherwise identical (Fig. 2d) had a profound reduction in activity.
The IC50 value in the cAMP assay for PEG-moPYYwas 10 nM(compared
to 0.42 nM for the digoxigeninylated peptide), i.e.was N20 fold less ac-
tive. This shows that digoxigenation of the PYY(3–36) analog has less
impact on its biological activity than PEGylation at the same position.
Furthermore, the improved potency of Dig-peptides vs PEG-peptides
is still seen upon complexation with bDigN antibody: The IC50 value
of the cAMP assay was 2.4 nM for the peptide–antibody complex com-
pared to 10 nM for the PEGylated peptide. Thus, the biological activity
in vitro was 4-fold better for the antibody complex compared to PEG-
peptide.3.5. Antibody complexation prolongs the serum half-life of Dig-Cy5 and
Dig-moPYY in vivo
To analyze if our antibody complexation technology improves
upon the limited stability in vivo and fast clearance of peptides
we determined the PK parameters of antibody complexes of the Dig-
moPYY peptide, as well as of the complexed ﬂuorophore Dig-Cy5
in vivo. The latter, Dig-Cy5, was applied as lowmolecular weight ‘surro-
gate’ for digoxigeninylated peptides, because its ﬂuorescent properties
allows easy and robust detection in the serum. For that, Dig-Cy5 or
antibody-complexed Dig-Cy5 (32.1 nmol) were injected intravenously
into female NRMI mice (25 g NRMI, 2 animals for each substance),
followed by alternate collection of 0.1 ml blood (approx. 40 μl serum)
0.08 h, 2 h, 4 h, and 24 h (see the Materials and methods section
for details). The Cy5-mediated ﬂuorescence values that we detected
for both mice 5 min after injection (T = 0.08 h) was set as 100%
value and ﬂuorescence values measured at subsequent time points
were expressed relative to that. The results of these analyses are
shown in Suppl. Fig. S4 and in Fig. 5a, with serum levels represented
as relative (%) levels of Cy5-mediated ﬂuorescence normalized to the
(peak) serum levels 5 min after injection. As expected for a compound
of rather smallmolecularweight, uncomplexedDig-Cy5 disappears rap-
idly from the serum. Less than 10% of the ﬂuorescence that was applied
(5 min value)was still detectable 2 h after injection, at later timepoints,
4 h and 24 h after injection, no Cy5-mediated signals were detectable.
In contrast to uncomplexed compound, antibody-complexed compound
wasdetectable at higher levels and at later timepoints. 2 h after injection,
ab






















Fig. 4. (a) cAMP agonist assays were performed with hNPY2R expressing HEK293 cells. Samples that were complexed with murine or humanized antibody do not show a difference
in activity. This indicates that Dig-binding is not contributed to the phenotype of the constant region of the antibody. hubDigN and mubDigN antibodies without peptide have no
potency in the cAMP accumulation assay. No difference in potency for the mubDigN–Dig-PYY complex (expt 1 and expt 2) was observed in independent assays on different
days. (b) Molecule composition and activity (Ec50 values) in cAMP assays.
53E. Hoffmann et al. / Journal of Controlled Release 171 (2013) 48–56stillmore than 50% of theﬂuorescence thatwas appliedwas detectable in
the serum. Cy5-mediated ﬂuorescence levels were also clearly detectable
at later time points (Suppl. Fig. S4). This indicates that antibodycomplexation signiﬁcantly increases the serum half-life of the small
compound Dig-Cy5. In another experiment (Fig. 5a) under identical
experimental conditions, Dig-Cy5 levels aswell as levels of the complexed
ab
Fig. 5. (a) Serum levels of Dig-Cy5 were determined by ﬂuorescence and huIgG levels
were determined by a human IgG speciﬁc ELISA. Values were normalized to peak levels
(5 min after i.v. injection), all other values are relative to that. (b) To detect Dig-peptide,
sera taken after i.v. injection of IgG-complexed (left panel) or uncomplexed (right panel)
Dig-peptide were subjected to SDS PAGE. The presence of Dig-peptide was detected by
Western blot with anti-Dig antibodies, using Dig-peptide as size controls (lanes 9 and
10). Additional signals were obtained at positions of higher molecular weight, indicating
that someDig-peptides became retained inprotein-rich regions of thegel. Thesehad similar
intensity ratios/differences between complexed and non-complexed peptides as observed
for the peptides at the expected positions on the gel.
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IgG speciﬁc ELISA and normalized to peak levels (5 min after i.v. injec-
tion). The results conﬁrm the rapid clearance of uncomplexed payload
and improved in vivo serum half-life/stability of the Dig-Cy5 payload
upon antibody complexation. A comparison of relative serum levels of
IgG and payload provide also evidence for ‘sustained-release’ like com-
plex dissociation since IgG levels decline slower than those of the payload
(Fig. 5a). To analyze the PK of antibody–peptide complexes, Dig-moPYY
or antibody-complexed Dig-moPYY (again 32.1 nmol) was injected
intravenously into female NRMI mice, followed by sampling following
the same schedule as for Dig-Cy5 (alternate 0.1 ml blood/40 μl serum at
0.08 h, 2 h, 4 h, and 24 h).
The assessment of Dig-moPYY in the serum proved to be more
challenging than that of Dig-Cy5 because we had no ‘direct’ detection
method. Therefore, we devised a reducing SDS-PAGE–Western-blot
assay to detect Dig-moPYY in serum (see the Materials and methodssection for details). Sample preparation for the SDS-PAGE included
exposure to high concentrations of SDS and reducing agents. Thereby,
Dig-peptides are effectively released from the denatured unfolded IgG.
After SDS-PAGE, separated proteins and Dig-peptides were blotted
and immobilized on membranes and Dig-peptides detected on the
membrane with anti-Dig antibodies (Fig. 5b). Due to the high protein
concentrations in serum and due to the rather small size of the Dig-
moPYY, signals do not appear as sharp bands. Nevertheless, selective
presence of signals in lanes of samples that contained peptides at early
time points unambiguously indicated the presence of Dig-peptide in
serum. Thus, the assay provides qualitative information, i.e. it allows to
specify the presence or absence of detectable amounts in serum. Under
these assay conditions, signals are detectable in serum of mice that
were injected with uncomplexed Dig-peptides at early time points
5 min, and to lower degrees at the 2 h and 4 h time points. 24 h after
injection almost no signal associated with Dig-moPYY can be detected
in sera of mice that received uncomplexed peptide. In contrast, sera of
mice that received complexed peptide showed signals not only at the
early time points, but also 24 h after injection signals were still clearly
detectable in these samples. Thus, antibody complexation improves not
only the pharmacokinetics of small ﬂuorescent compounds, but also
that of digoxigeninylated peptides.
3.6. Antibody complexation improves the potency of a PYY peptide in vivo
To evaluate the impact of the PK modulation that we achieved by
antibody complexation (Fig. 5) on their therapeutic potency, we deter-
mined the in vivo biological activity of peptide–antibody complexes and
compared themwith that of uncomplexed peptides in a DIOmodel [24]
(see the Materials and methods section for experimental details). PYY
derived peptides can reduce the food intake in DIO mice, presumably
mediated by Y2 receptor signaling [22]. Therefore, biological efﬁcacy
of PYY-derivatives as NPY2 receptor agonists can be assessed by their
effect on food intake in this model. Peptide-mediated activity is
reﬂected bymodulated food intake in this model with decreased intake
being indicative for therapeutic efﬁcacy, unchanged or increased
food intake corresponding to low or no efﬁcacy. Fig. 6 shows that
uncomplexed peptide has only a very small effect on food intake at an
early time point (1 h) in this animal model, which correlates with its
rapid clearance (Fig. 5). In contrast, we observed that application of
the antibody complexed peptide (with increased serum half-life,
Fig. 5) caused a strikingly reduced food-intake of treated animals.
Furthermore, this reduction in food intake was seen for an extended
period of time, the effect lasting up to 48 h after dosing. Application of
the antibody alone (control) had no effect on food intake. The effect
on food intake of the antibody complexed peptide was observed at
doses that were on a molar level 20-fold lower than those of the
unmodiﬁed peptide. This indicates that antibody complexation of the
haptenylated peptide improves its therapeutic efﬁcacy.
4. Discussion
The pharmacokinetics of peptides can be modulated by hapten
coupling and subsequent generation of non-covalent complexes with
hapten binding antibodies. The hapten–antibody system that we ap-
plied is based upon an established digoxigenin-binding antibody and
matching reagents for digoxigeninylation [14–16]. The hapten com-
plexation approach differs from other PK modulating peptide conjuga-
tion technologies in several aspects: (i) peptide–hapten coupling is
done via ‘synthetic chemistry’ and not via protein-conjugation technol-
ogy, (ii) coupling of the haptenylated peptide to the antibody occurs at
deﬁned positions with a deﬁned 2:1 stoichiometry, and (iii) coupling
to the antibody is achieved in a non-covalent manner.
The coupling of long unstructured polymer chains such as PEG
to peptides is frequently accompanied by profound loss of potency.
This was also observed for PEGylated PYY derivatives [18]. In contrast
Fig. 6. Increased efﬁcacy in vivo of antibody-complexed peptides: (a) interval food
intake in DIO mice treated with antibody, peptide and antibody complexed peptide and
(b) interval food intake in DIO mice treated with uncomplexed or antibody-complexed
peptide. The treatment group that received antibody complexes received a 17-fold lower
dose of complexed peptide.
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of the PYY peptide generated entities withmore potency than the corre-
sponding PEGylated derivative. On the other hand, haptenylation by
itself is not sufﬁcient to achieve PK modulation. Subsequent generation
of complexes with a hapten-binding antibody is necessary for that.
These complexes differ from ‘classical’ conjugates [8,9], from covalently
linked peptides [12,13], and from fusion proteins [3–5] in that peptide
and antibody are held together in a non-covalent manner. This permits
the coupling of peptide derivatives (and of other payloads) harboring
non-natural amino acids or modiﬁcations which cannot be generated
by the protein synthesis machinery of cells. In contrast, recombinant
fusion to Fc's or immunoglobulin- or albumin-binding domains [3–5]
mandate that payloads are composed of ‘translatable’ linear sequence
stretches composed of normal amino acids (and which permit N- or
C-terminal fusion without major activity loss). This and focus on ‘non-
translatable’ structures differentiate our platform from recombinant
fusion protein platforms (which by themselves can effectively modulate
the PK of proteins or peptide stretches composed of normal amino acids)
[25,26,7]. The strengths of this non-covalent antibody–hapten in-
teraction determines the stability of antibody complexes in vitro
and in vivo. Antibody on- and off-rates are relevant for afﬁnity,
with off-rates determining the release of bound hapten from the
antibody (and on-rates determining potential re-binding of released hap-
ten). Even antibodies with high afﬁnities will eventually release payload
after some time. Thus, the general principle of PK modulation via non-covalent complexation may be considered similar to a sustained release
principle: Payload becomes released from the antibody (off-reaction
which is determined by the antibody off-rate), and can either travel and
act as separate entity, or become re-bound (determined by on-rate) and
hence again become PK-modulated by the antibody. The option to release
the peptide can be advantageous, e.g. enabling the small peptide to reach
locations that are difﬁcult to access as part of a large protein entity. The
balance of on- and off-rates will thereby determine the slow-release
properties and ratio between free and antibody complexed payload.
The Dig-binding antibodies that we applied in this study have low nM
kD afﬁnities [16], and hence at are not ‘super-high’ afﬁnity antibodies.
Because the ratio between free and complexed payload of this system is
inﬂuenced by the balance of on- and off-rates, it may be possible
to modulate its slow-release ‘PK-buffer’ properties by varying afﬁn-
ities, e.g. via afﬁnity maturation techniques [28] Protein- or hapten-
engineering techniques may also be applied to change binding
valencies, with bi-hapten constructs for avidity-mediated off-rate
modulation of payloads, or monovalent antibody constructs for
‘non-redundant’ payload display (bivalent payload presentation
by itself may already inﬂuence its potency). An increase in afﬁnity
would switch the balance of the ‘PK-buffer’more towards a technology
with features similar to stable fusion proteins [3,4,27] or conjugates.
In contrast, reducing afﬁnities would generate entities with increased
release and reduced serum half live. Peptide derivatives or other
hapten-bound payloads that are complexed with antibodies are not
part of antibody-derived protein fragments after proteolytic degrada-
tion. Therefore, in contrast to covalently coupled structures, they cannot
easily be displayed by antigen-presenting cells to the immune system.
Thus, non-covalent antibody complexation may potentially carry a
lower immunogenicity risk than covalent protein conjugates or fusions.
Aggregated haptenylated peptides may still elicit immune responses
not only to the peptide derivative but also to a hapten. A solution to
this issue may be the application of other ‘haptens’ that are similar
to human structures. And antibody complexation may also by itself
reduce the aggregation propensity of peptides. There is one profound
difference between non-covalent antibody complexation and other
‘sustained release’ principles: sustained release formulations generally
let go of their payload in a unidirectional manner. Once released,
the peptide will follow its own PK rules. In contrast, hapten binding
antibodies which have ‘lost’ their payload are capable to re-bind
haptenylated peptides in the circulation. Thus, antibody binding and
release may serve as a ‘PK-buffer’ for therapeutic peptides. Even though
digoxigenin shows lower activity than digoxin, it still is cardioactive
[29]. Hence, it might elicit biological responses independent from or in
addition to attached payloads if applied in sufﬁcient concentrations.
On the other hand, antibody-complexes completely cover the Dig
upon which it is inaccessible (see Fig. 1b). Anti-Dig antibodies are in
fact applied as drugs to counteract Dig-mediated toxicity [30]. Slow
release generates free Dig-payload at levels that we expect to be well
below critical concentrations. Another option to modulate or extend
this platform (and to eliminate any potential Dig-related concerns)
would be to use antibodies which recognize other haptens that carry
no pharmacological activity by themselves.Acknowledgments
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